Cell loss no greater with femtosecond lasers

Article

Penetrating keratoplasty (PK) with a femtosecond laser offers good surgical results and endothelial cell loss numbers similar to those found for PK using standard trephines.

Penetrating keratoplasty (PK) with a femtosecond laser offers good surgical results and endothelial cell loss numbers similar to those found for PK using standard trephines, according to Mike Holzer and co-workers at the International Vision Correction Research Centre, Heidelberg University, Germany.

Eleven eyes of 10 subjects underwent uneventful PK with a femtosecond laser. Endothelial cell counts were taken on the corneal donor buttons prior to surgery and measurements were taken at 12 and 24 months postoperatively using a specular microscope.

Preoperative cell counts ranged between 2,300 and 2,750 cells/mm2. At 24 months postoperatively, all corneal transplants were clear and visual acuity had improved from preoperative levels. The postoperative cell counts ranged between 1,350 and 2,100 cells/mm2, whilst the median cell loss was recorded as 35.9%.

It was concluded that cell loss is similar in patients undergoing PK with a femtosecond laser and in those undergoing treatment using conventional trephines.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.